RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 2.7 Million USD | 30.43% |
| 2021 | 2.07 Million USD | 23.4% |
| 2020 | 1.68 Million USD | 4.03% |
| 2019 | 1.61 Million USD | 32.96% |
| 2018 | 1.21 Million USD | 14.35% |
| 2017 | 1.06 Million USD | 5.25% |
| 2016 | 1.01 Million USD | 24.8% |
| 2015 | 810.01 Thousand USD | 95.77% |
| 2014 | 413.74 Thousand USD | -28.9% |
| 2013 | 581.95 Thousand USD | 85.8% |
| 2012 | 313.21 Thousand USD | 119.44% |
| 2011 | -1.61 Million USD | -55.26% |
| 2010 | -1.03 Million USD | -358.15% |
| 2009 | -226.46 Thousand USD | 84.17% |
| 2008 | -1.43 Million USD | 64.41% |
| 2007 | -4.02 Million USD | -143.78% |
| 2006 | -1.64 Million USD | 20.03% |
| 2005 | -2.06 Million USD | 77.48% |
| 2004 | -9.15 Million USD | -713.94% |
| 2003 | -1.12 Million USD | 39.15% |
| 2002 | -1.84 Million USD | 59.43% |
| 2001 | -4.55 Million USD | -68.49% |
| 2000 | -2.7 Million USD | -3107.35% |
| 1999 | 89.94 Thousand USD | 107.65% |
| 1998 | -1.17 Million USD | 81.84% |
| 1997 | -6.47 Million USD | -112.7% |
| 1996 | -3.04 Million USD | -438.25% |
| 1995 | 900 Thousand USD | 550.0% |
| 1994 | -200 Thousand USD | 83.33% |
| 1993 | -1.2 Million USD | 40.0% |
| 1992 | -2 Million USD | 13.04% |
| 1991 | -2.3 Million USD | 14.81% |
| 1990 | -2.7 Million USD | -1250.0% |
| 1989 | -200 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 2.85 Million USD | 5.36% |
| 2023 Q2 | 2.86 Million USD | 0.43% |
| 2023 Q3 | 2.2 Million USD | -22.98% |
| 2022 Q1 | 2.43 Million USD | 17.45% |
| 2022 FY | 2.7 Million USD | 30.43% |
| 2022 Q4 | 2.7 Million USD | 6.0% |
| 2022 Q3 | 2.55 Million USD | 5.6% |
| 2022 Q2 | 2.41 Million USD | -0.79% |
| 2021 FY | 2.07 Million USD | 23.4% |
| 2021 Q4 | 2.07 Million USD | 11.93% |
| 2021 Q1 | 1.55 Million USD | -7.67% |
| 2021 Q3 | 1.85 Million USD | 11.98% |
| 2021 Q2 | 1.65 Million USD | 6.63% |
| 2020 Q1 | 1.49 Million USD | -7.41% |
| 2020 Q3 | 1.64 Million USD | 21.52% |
| 2020 Q4 | 1.68 Million USD | 2.3% |
| 2020 FY | 1.68 Million USD | 4.03% |
| 2020 Q2 | 1.35 Million USD | -9.62% |
| 2019 FY | 1.61 Million USD | 32.96% |
| 2019 Q3 | 1.52 Million USD | 0.85% |
| 2019 Q1 | 1.42 Million USD | 17.18% |
| 2019 Q2 | 1.51 Million USD | 6.17% |
| 2019 Q4 | 1.61 Million USD | 5.97% |
| 2018 Q2 | 1.23 Million USD | -7.05% |
| 2018 Q1 | 1.33 Million USD | 25.38% |
| 2018 Q4 | 1.21 Million USD | 9.41% |
| 2018 Q3 | 1.11 Million USD | -10.32% |
| 2018 FY | 1.21 Million USD | 14.35% |
| 2017 Q4 | 1.06 Million USD | -9.99% |
| 2017 FY | 1.06 Million USD | 5.25% |
| 2017 Q3 | 1.18 Million USD | -1.42% |
| 2017 Q2 | 1.19 Million USD | 21.58% |
| 2017 Q1 | 986.18 Thousand USD | -2.44% |
| 2016 Q1 | 1.12 Million USD | 39.03% |
| 2016 Q4 | 1.01 Million USD | -18.98% |
| 2016 FY | 1.01 Million USD | 24.8% |
| 2016 Q3 | 1.24 Million USD | 88.58% |
| 2016 Q2 | 661.63 Thousand USD | -41.25% |
| 2015 Q4 | 810.01 Thousand USD | 116.0% |
| 2015 Q2 | 970.04 Thousand USD | 59.35% |
| 2015 Q1 | 608.76 Thousand USD | 47.14% |
| 2015 FY | 810.01 Thousand USD | 95.77% |
| 2015 Q3 | 375.01 Thousand USD | -61.34% |
| 2014 Q4 | 413.74 Thousand USD | -17.58% |
| 2014 FY | 413.74 Thousand USD | -28.9% |
| 2014 Q1 | 215.03 Thousand USD | -63.05% |
| 2014 Q3 | 502 Thousand USD | 26.52% |
| 2014 Q2 | 396.77 Thousand USD | 84.51% |
| 2013 Q4 | 581.95 Thousand USD | 10.16% |
| 2013 Q2 | 787.97 Thousand USD | 75.52% |
| 2013 Q1 | 448.93 Thousand USD | 43.33% |
| 2013 FY | 581.95 Thousand USD | 85.8% |
| 2013 Q3 | 528.25 Thousand USD | -32.96% |
| 2012 Q4 | 313.21 Thousand USD | 127.49% |
| 2012 Q3 | 137.68 Thousand USD | 152.75% |
| 2012 Q2 | -261 Thousand USD | 66.47% |
| 2012 Q1 | -778.44 Thousand USD | 51.68% |
| 2012 FY | 313.21 Thousand USD | 119.44% |
| 2011 Q1 | -1.58 Million USD | -53.18% |
| 2011 Q2 | -1.41 Million USD | 10.68% |
| 2011 Q4 | -1.61 Million USD | -267.48% |
| 2011 Q3 | -438.38 Thousand USD | 69.12% |
| 2011 FY | -1.61 Million USD | -55.26% |
| 2010 FY | -1.03 Million USD | -358.15% |
| 2010 Q4 | -1.03 Million USD | 54.07% |
| 2010 Q3 | -2.25 Million USD | 11.82% |
| 2010 Q2 | -2.56 Million USD | 61.16% |
| 2010 Q1 | -6.59 Million USD | -2813.01% |
| 2009 Q2 | -887.85 Thousand USD | 45.26% |
| 2009 FY | -226.46 Thousand USD | 84.17% |
| 2009 Q1 | -1.62 Million USD | -13.35% |
| 2009 Q4 | -226.46 Thousand USD | 79.06% |
| 2009 Q3 | -1.08 Million USD | -21.8% |
| 2008 Q3 | -2.79 Million USD | 32.3% |
| 2008 Q4 | -1.43 Million USD | 48.83% |
| 2008 FY | -1.43 Million USD | 64.41% |
| 2008 Q1 | -3.6 Million USD | 10.25% |
| 2008 Q2 | -4.13 Million USD | -14.46% |
| 2007 Q4 | -4.02 Million USD | 45.9% |
| 2007 Q1 | -2.94 Million USD | -78.75% |
| 2007 FY | -4.02 Million USD | -143.78% |
| 2007 Q2 | -2.09 Million USD | 29.11% |
| 2007 Q3 | -7.43 Million USD | -255.57% |
| 2006 FY | -1.64 Million USD | 20.03% |
| 2006 Q3 | -2.47 Million USD | -40.31% |
| 2006 Q2 | -1.76 Million USD | 73.26% |
| 2006 Q1 | -6.58 Million USD | -219.36% |
| 2006 Q4 | -1.64 Million USD | 33.26% |
| 2005 Q4 | -2.06 Million USD | 29.83% |
| 2005 Q3 | -2.93 Million USD | -234.16% |
| 2005 Q1 | -2.85 Million USD | 99.97% |
| 2005 Q2 | -879.56 Thousand USD | 69.15% |
| 2005 FY | -2.06 Million USD | 77.48% |
| 2004 Q2 | -9.97 Million USD | 50.28% |
| 2004 FY | -9.15 Million USD | -713.94% |
| 2004 Q1 | -20.06 Million USD | -313.99% |
| 2004 Q3 | -11.41 Million USD | -14.41% |
| 2004 Q4 | -9.15 Billion USD | -80126.11% |
| 2003 Q3 | -4.46 Million USD | -297.22% |
| 2003 Q2 | -1.12 Million USD | -551.99% |
| 2003 Q4 | -4.84 Million USD | -8.47% |
| 2003 FY | -1.12 Million USD | 39.15% |
| 2003 Q1 | -172.55 Thousand USD | 61.08% |
| 2002 Q1 | -2.46 Million USD | 24.09% |
| 2002 FY | -1.84 Million USD | 59.43% |
| 2002 Q4 | -443.32 Thousand USD | 62.85% |
| 2002 Q3 | -1.19 Million USD | 35.46% |
| 2002 Q2 | -1.84 Million USD | 25.12% |
| 2001 Q3 | -3.15 Million USD | 30.83% |
| 2001 Q1 | -4.87 Million USD | 14.3% |
| 2001 FY | -4.55 Million USD | -68.49% |
| 2001 Q2 | -4.55 Million USD | 6.59% |
| 2001 Q4 | -3.25 Million USD | -3.19% |
| 2000 Q1 | -617.41 Thousand USD | -242.45% |
| 2000 FY | -2.7 Million USD | -3107.35% |
| 2000 Q4 | -5.69 Million USD | -111.44% |
| 2000 Q3 | -2.69 Million USD | 0.45% |
| 2000 Q2 | -2.7 Million USD | -338.11% |
| 1999 Q3 | 375.2 Thousand USD | 316.89% |
| 1999 Q1 | -460 Thousand USD | -176.67% |
| 1999 FY | 89.94 Thousand USD | 107.65% |
| 1999 Q4 | 433.43 Thousand USD | 15.52% |
| 1999 Q2 | 90 Thousand USD | 119.57% |
| 1998 Q1 | -1.6 Million USD | 11.11% |
| 1998 Q4 | 600 Thousand USD | 700.0% |
| 1998 Q3 | -100 Thousand USD | 91.49% |
| 1998 FY | -1.17 Million USD | 81.84% |
| 1998 Q2 | -1.17 Million USD | 26.52% |
| 1997 Q4 | -1.8 Million USD | 53.85% |
| 1997 FY | -6.47 Million USD | -112.7% |
| 1997 Q1 | -3.6 Million USD | -414.29% |
| 1997 Q2 | -6.47 Million USD | -79.86% |
| 1997 Q3 | -3.9 Million USD | 39.77% |
| 1996 Q3 | -1.8 Million USD | 40.87% |
| 1996 Q4 | -700 Thousand USD | 61.11% |
| 1996 Q2 | -3.04 Million USD | -79.07% |
| 1996 Q1 | -1.7 Million USD | -288.89% |
| 1996 FY | -3.04 Million USD | -438.25% |
| 1995 Q3 | 900 Thousand USD | 0.0% |
| 1995 Q4 | 900 Thousand USD | 0.0% |
| 1995 FY | 900 Thousand USD | 550.0% |
| 1995 Q1 | -10 Thousand USD | 87.5% |
| 1995 Q2 | 900 Thousand USD | 9100.0% |
| 1994 Q4 | -80 Thousand USD | 84.0% |
| 1994 Q1 | -800 Thousand USD | 75.76% |
| 1994 Q2 | -200 Thousand USD | 75.0% |
| 1994 Q3 | -500 Thousand USD | -150.0% |
| 1994 FY | -200 Thousand USD | 83.33% |
| 1993 Q3 | -310 Thousand USD | 74.17% |
| 1993 Q1 | -1.3 Million USD | 34.34% |
| 1993 Q4 | -3.3 Million USD | -964.52% |
| 1993 FY | -1.2 Million USD | 40.0% |
| 1993 Q2 | -1.2 Million USD | 7.69% |
| 1992 Q2 | -2 Million USD | -1.52% |
| 1992 Q3 | -1.11 Million USD | 44.5% |
| 1992 FY | -2 Million USD | 13.04% |
| 1992 Q4 | -1.98 Million USD | -78.38% |
| 1992 Q1 | -1.97 Million USD | -149.37% |
| 1991 Q3 | -1.4 Million USD | 39.13% |
| 1991 Q4 | -790 Thousand USD | 43.57% |
| 1991 FY | -2.3 Million USD | 14.81% |
| 1991 Q1 | -1.09 Million USD | -55.71% |
| 1991 Q2 | -2.3 Million USD | -111.01% |
| 1990 Q3 | -1.35 Million USD | 50.0% |
| 1990 FY | -2.7 Million USD | -1250.0% |
| 1990 Q1 | -1.8 Million USD | 23.08% |
| 1990 Q2 | -2.7 Million USD | -50.0% |
| 1990 Q4 | -700 Thousand USD | 48.15% |
| 1989 Q3 | -1.2 Million USD | -500.0% |
| 1989 Q2 | -200 Thousand USD | 0.0% |
| 1989 Q4 | -2.34 Million USD | -95.0% |
| 1989 FY | -200 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 206864.504% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 52.046% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 93.67% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1185.095% |
| Rebus Holdings, Inc. | 305 Thousand USD | -788.07% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 142.963% |
| Qrons Inc. | 351.42 Thousand USD | -670.748% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -335.214% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 93.764% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 13372.32% |
| Skye Bioscience, Inc. | -5.72 Million USD | 147.342% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 82.817% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 34.225% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -574.038% |
| SQZ Biotechnologies Company | -36.23 Million USD | 107.475% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -20.8% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -192.133% |
| Mesoblast Limited | 55.85 Million USD | 95.151% |
| Marizyme, Inc. | 18.56 Million USD | 85.413% |
| Genus plc | 190.6 Million USD | 98.579% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -21.146% |
| Pharming Group N.V. | 109.8 Million USD | 97.533% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -214.867% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -123.135% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -298.326% |
| ContraFect Corporation | -6.02 Million USD | 144.949% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1911.761% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -134.425% |
| IMV Inc. | 7.67 Million USD | 64.688% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 50.769% |
| MultiCell Technologies, Inc. | 90.04 USD | -3008135.229% |
| ONE Bio Corp. | 9.04 Million USD | 70.038% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 469.032% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 79.078% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -98.002% |
| Q BioMed Inc. | 4.06 Million USD | 33.285% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 91.135% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -168.788% |
| Biomind Labs Inc. | 711.4 Thousand USD | -280.743% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 95.526% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -35.472% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 78.85% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -653.0% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1837.437% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -13533.739% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -23.008% |
| GB Sciences, Inc. | 1.74 Million USD | -55.016% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1573.771% |
| HST Global, Inc. | 96.79 Thousand USD | -2698.358% |
| CSL Limited | 10.52 Billion USD | 99.974% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1213.478% |
| Halberd Corporation | 144.72 Thousand USD | -1771.612% |
| Enzolytics Inc. | 981.65 Thousand USD | -175.923% |
| Agentix Corp. | 37.63 Thousand USD | -7097.829% |
| Resverlogix Corp. | 6.45 Million USD | 58.012% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 502.416% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.134% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 105.762% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 61.694% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 130.641% |
| AVAX Technologies, Inc. | -5.9 Million USD | 145.884% |
| Zenith Capital Corp. | 10.06 Thousand USD | -26813.901% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.255% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1251.389% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -13.52% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1546.484% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 14886.631% |
| Kadimastem Ltd | -253.1 Thousand USD | 1170.167% |
| Helix BioMedix, Inc. | -2.57 Million USD | 205.392% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 86.641% |
| BioStem Technologies, Inc. | 4.47 Million USD | 39.432% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1245.869% |
| LadRx Corporation | -2.03 Million USD | 233.005% |
| Cell Source, Inc. | 9.23 Million USD | 70.66% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -326.441% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -326.441% |
| NovAccess Global Inc. | 2.17 Million USD | -24.336% |
| Affymax, Inc. | -5.59 Million USD | 148.394% |
| Itoco Inc. | 228.3 Thousand USD | -1086.402% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1891.79% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 45.358% |
| Mobile Lads Corp. | 484.23 Thousand USD | -459.363% |
| CytoDyn Inc. | 20.26 Million USD | 86.632% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 418742.195% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 29324.381% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 64.851% |
| SYBLEU INC | 473.71 Thousand USD | -471.783% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 39.228% |
| International Stem Cell Corporation | 2.59 Million USD | -4.58% |
| Bioxytran, Inc. | 1.89 Million USD | -42.64% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4239.825% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -24.197% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 21.124% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 68.331% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -250.581% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 316.689% |
| Neutra Corp. | 52.18 Thousand USD | -5090.21% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 208.823% |
| PureTech Health plc | -167.19 Million USD | 101.62% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1205.972% |
| IXICO plc | -4.44 Million USD | 160.942% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 79.51% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.062% |
| CSL Limited | 10.52 Billion USD | 99.974% |
| Cellectis S.A. | -43.81 Million USD | 106.181% |